Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Other Medical Devices
elastagen.com

See what CB Insights has to offer

Founded Year

2003

Stage

Acquired | Acquired

Total Raised

$21.59M

Valuation

$0000 

About Elastagen

Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial. The company's platform technology has potential applications in a number of areas including skin rejuvenation, scar remodeling, skin tissue repair and wound healing, and, surgical glues/sealants.

Elastagen Headquarter Location

National Innovation Centre 4 Cornwallis Street, Eveleigh

Sydney, New South Wales, 2015,

Australia

+61 (0)2 9209 4054

Latest Elastagen News

CICADA TURNS 20: How synthetic skin biotech Elastagen changed lives

Sep 14, 2020

CICADA TURNS 20: How synthetic skin biotech Elastagen changed lives MENUMENU September 6, 2020 Sally-Ann Williams - September 14, 2020 2 MIN READ This year marks the 20th anniversary of Australia’s first ever incubator, Cicada Innovations . To date, Cicada Innovations has incubated over 100 startups, and helped more than 300 companies raise over $450 million in venture capital and government grants, create hundreds of jobs, build local manufacturing capability, file more than 500 patents and trademarks, and launch more than 700 deep tech innovations globally (more information here ). In celebration of 20 years of fostering Australian innovation, Startup Daily is running a 5-part series – this is no. 2 – highlighting some of the individual companies produced by the incubator. In 2008, a little-known biotech named Elastagen entered the Cicada incubator in the hopes of commercialising its work on human tropoelastin (TE), the precursor of elastin – a key component of youthful skin. It has since become the first company in the world to have succeeded in the scalable, commercial, clinical-grade manufacture of TE, and it’s application in medical treatments. But this didn’t happen overnight. Elastagen had its beginnings in 1997, when University of Sydney professor Tony Weiss patented his research into medical applications of the protein TE after realising its potential in repairing human skin. Over the following decade, Weiss and a broader team developed methods of manufacturing TE and approaches to formulating it for clinical uses. In 2008 to 2009, the technology was transferred to Elastagen, where Cicada Innovations supported the incoming CEO, Rob Daniels, who led the team raise Series A funding from GBS Venture Partners and Brandon Capital Partners. Elastagen was now based out of Cicada Innovations, with growing international clinical, manufacturing, and regulatory operations. Led by Rob Daniels, the Elastagen team developed novel injectable TE formulations and developed a pipeline of target indications, including acne scarring, stretchmarks, aesthetics (skin quality) and, with support from NSW Health, burns and chronic wounds. Clinical studies in Australia and Europe demonstrated their safety and efficacy, and Elastagen was also one of the inaugural recipients of NSW State Government Medical Devices Fund in 2013. After a period of collaboration with the Elastagen team, US biopharmaceutical giant Allergan acquired Elastagen in 2018 for over $350 million in total deal value. Allergan acquired Elastagen primarily for the injectable product portfolio (acne scars/stretch marks aesthetics). The sale is a major step in bringing Elastagen’s technologies to patients. During this time, multiple sources of finance were vital to supporting product development, market research, and clinical trials as the company’s technology matured. This included state and federal government funding and venture capital from investors in Australia, Korea, Japan, UK and the US. At the time of its sale, Elastagen was owned by the University of Sydney and local and international investors including Cicada Innovations, Brandon, and GBS. Speaking to the sale, USYD professor and owner of the underlying research, Tony Weiss, said it was “one of the largest healthcare sales of this type in Australian history”. He continued to explain that “a substantial portion of the hundreds of millions of dollars in proceeds will be returned to Australian superannuation funds and the venture capital firms that took the risk of investing in early-stage technology commercialisation. This will have a multiplier effect, increasing confidence amongst venture capital firms, funds, and venture-capital-backed companies in investing in the next generation of life science technologies.” And this is the beauty of companies like Elastagen. Elastagen demonstrates the potential of deep tech to not only be an enormous commercial success, and to deliver on solving a significant medical problem, but also to benefit broader society in multiple compounding ways.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Elastagen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Elastagen is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

7,872 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Elastagen Patents

Elastagen has filed 8 patents.

The 3 most popular patent topics include:

  • Cell biology
  • Clusters of differentiation
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/24/2018

8/10/2021

Clusters of differentiation, Transcription factors, Cell biology, Human proteins, Traumatology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/24/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/10/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Transcription factors, Cell biology, Human proteins, Traumatology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.